Acetavance (acetaminophen) / Mallinckrodt - LARVOL DELTA

19-C-0042: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2026 ➔ Jun 2029

Trial completion date • Hairy Cell Leukemia • Hematological Malignancies • Leukemia • Oncology

Potential Economic and Clinical Implications of Multi-Dose Intravenous Acetaminophen After Robotic-Assisted Prostatectomy: A Secondary Descriptive Analysis of Publicly Available Phase IV Trial Data (NCT02369211). (PubMed, Healthcare (Basel)) - P4 | "Introduction: This study evaluated the implications of intravenous acetaminophen (Ofirmev) on perioperative outcomes in patients undergoing robotic-assisted laparoscopic prostatectomy (RALP) for prostate cancer...Primary endpoints were hospital and post-anesthesia care unit (PACU) LOS; secondary endpoints included postoperative pain scores and opioid consumption (morphine milligram equivalents)...Although pain scores and opioid use numerically favored IV acetaminophen, these differences were not statistically significant. The reported difference in hospital LOS was statistically significant in the original trial record but clinically minimal; therefore, the findings should be interpreted as exploratory and hypothesis-generating regarding potential operational and economic implications."

Clinical • Journal • P4 data • Addiction (Opioid and Alcohol) • Anesthesia • Genito-urinary Cancer • Oncology • Pain • Prostate Cancer • Solid Tumor

NCI-2022-02215: A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure (clinicaltrials.gov) - P2 | N=51 | Terminated | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Dec 2026 ➔ May 2026 | Active, not recruiting ➔ Terminated | Trial primary completion date: Dec 2026 ➔ May 2026; <75% participation

Minimal residual disease • Trial completion date • Trial primary completion date • Trial termination • Acute Myelogenous Leukemia • Myelodysplastic Syndrome • IL3RA

19-C-0042: Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia (clinicaltrials.gov) - P1 | N=18 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jun 2025 ➔ Jun 2026

Trial completion date • Hairy Cell Leukemia • Hematological Malignancies • Leukemia • Oncology

Opioid Sparing Anesthesia Care for Pediatric Patients Having Tonsil Surgery (clinicaltrials.gov) - P=N/A | N=62 | Completed | Sponsor: Boston Children's Hospital | Recruiting ➔ Completed

Head-to-Head • Trial completion • Anesthesia • CNS Disorders • Infectious Disease • Otorhinolaryngology • Pain • Pediatrics

IV vs Oral Acetaminophen in Spine Fusion Perioperative Care (clinicaltrials.gov) - P4 | N=166 | Completed | Sponsor: Hospital for Special Surgery, New York | Enrolling by invitation ➔ Completed

HEOR • Trial completion • Pain

PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients (clinicaltrials.gov) - P3 | N=900 | Completed | Sponsor: Beth Israel Deaconess Medical Center | Active, not recruiting ➔ Completed | Trial primary completion date: Mar 2025 ➔ Mar 2026

Trial completion • Trial primary completion date • Cardiovascular • CNS Disorders • Coronary Artery Disease

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - P2 | N=34 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed

Monotherapy • Trial completion • Alveolar Soft Tissue Sarcoma • Oncology • Sarcoma • Solid Tumor

BETWEEN THE LAYERS: INTRACRANIAL SUBDURAL HEMATOMA FOLLOWING EPIDURAL ANESTHESIA (CHEST 2025) - "She denied neurological deficits, bowel or bladder incontinence, and was managed conservatively with Fioricet, Ofirmev, Motrin, Theophylline, and IV fluids, but symptoms persisted without relief...Neurosurgery was consulted, and Keppra was initiated alongside ICU admission for close monitoring... Early recognition and management of such rare complications are crucial to prevent further deterioration, including the risk of herniation, as seen in this patient. Recognizing this rare but critical complication requires maintaining high index of suspicion when evaluating postpartum patients presenting with headaches after epidural anesthesia."

Anesthesia • Cardiovascular • CNS Disorders • Gynecology • Hematological Disorders • Musculoskeletal Pain • Thrombosis • Urinary Incontinence

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (clinicaltrials.gov) - P1/2 | N=34 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Dec 2027 ➔ Mar 2025

Trial completion • Trial completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • ABL1 • ASXL1 • BCR • CD34 • FLT3 • HLA-B • HLA-C

NCI-2022-02215: A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure (clinicaltrials.gov) - P2 | N=42 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Recruiting ➔ Active, not recruiting

Enrollment closed • Minimal residual disease • Acute Myelogenous Leukemia • Myelodysplastic Syndrome • IL3RA

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers (clinicaltrials.gov) - P1/2 | N=37 | Completed | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Completed | Trial completion date: Jan 2027 ➔ Mar 2025

Trial completion • Trial completion date • Tumor mutational burden • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (clinicaltrials.gov) - P2 | N=34 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Mar 2025 ➔ Mar 2026

Monotherapy • Trial completion date • Alveolar Soft Tissue Sarcoma • Oncology • Sarcoma • Solid Tumor

IV vs Oral Acetaminophen in Spine Fusion Perioperative Care (clinicaltrials.gov) - P4 | N=166 | Enrolling by invitation | Sponsor: Hospital for Special Surgery, New York | Trial completion date: Mar 2025 ➔ Mar 2026 | Trial primary completion date: Mar 2025 ➔ Mar 2026

HEOR • Trial completion date • Trial primary completion date • Pain

PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients (clinicaltrials.gov) - P3 | N=900 | Active, not recruiting | Sponsor: Beth Israel Deaconess Medical Center | Recruiting ➔ Active, not recruiting

Enrollment closed • Cardiovascular • CNS Disorders • Coronary Artery Disease

PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients (clinicaltrials.gov) - P3 | N=900 | Recruiting | Sponsor: Beth Israel Deaconess Medical Center | Trial completion date: Oct 2024 ➔ Jan 2026 | Trial primary completion date: Oct 2024 ➔ Jan 2025

Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Coronary Artery Disease

A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache (clinicaltrials.gov) - P4 | N=0 | Withdrawn | Sponsor: Spectrum Health - Lakeland | N=500 ➔ 0 | Terminated ➔ Withdrawn

Enrollment change • Trial withdrawal • Migraine • Pain

Opioid Sparing Anesthesia Care for Pediatric Patients Having Tonsil Surgery (clinicaltrials.gov) - P=N/A | N=58 | Recruiting | Sponsor: Boston Children's Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Head-to-Head • Surgery • Anesthesia • CNS Disorders • Infectious Disease • Otorhinolaryngology • Pain • Pediatrics

IV vs Oral Acetaminophen in Spine Fusion Perioperative Care (clinicaltrials.gov) - P4 | N=166 | Enrolling by invitation | Sponsor: Hospital for Special Surgery, New York | Trial completion date: Mar 2024 ➔ Mar 2025 | Trial primary completion date: Mar 2024 ➔ Mar 2025

HEOR • Trial completion date • Trial primary completion date • Pain

Opioid Sparing Anesthesia Care for Pediatric Patients Having Tonsil Surgery (clinicaltrials.gov) - P=N/A | N=58 | Not yet recruiting | Sponsor: Boston Children's Hospital

Head-to-Head • New trial • Surgery • Anesthesia • CNS Disorders • Infectious Disease • Otorhinolaryngology • Pain • Pediatrics

POPCORN: Postoperative Pain Control & Relief in Neonates (clinicaltrials.gov) - P4 | N=11 | Terminated | Sponsor: St. Louis University | Active, not recruiting ➔ Terminated; Involved investigators no longer at the investigating center

Trial termination • Pain

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Medication Use Evaluation of Ofirmev (ASHP 2023) - No abstract available

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: M.D. Anderson Cancer Center

Combination therapy • New P2 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

Post-op Acetaminophen vs NSAID Use on Lumbar Spinal Fusion Outcomes (clinicaltrials.gov) - P=N/A | N=178 | Completed | Sponsor: Hospital for Special Surgery, New York | Active, not recruiting ➔ Completed | N=300 ➔ 178

Enrollment change • Trial completion • CNS Disorders • Immunology • Musculoskeletal Diseases • Orthopedics • Osteoarthritis • Pain • Rheumatology • CORIN